Cyclophosphamide in the treatment of focal segmental glomerulosclerosis
Autor(a) principal: | |
---|---|
Data de Publicação: | 2004 |
Outros Autores: | , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Institucional da UFBA |
Texto Completo: | http://www.repositorio.ufba.br/ri/handle/ri/4801 |
Resumo: | p.1365-1372 |
id |
UFBA-2_dceaa447eaec308f07e15c392b84bc81 |
---|---|
oai_identifier_str |
oai:repositorio.ufba.br:ri/4801 |
network_acronym_str |
UFBA-2 |
network_name_str |
Repositório Institucional da UFBA |
repository_id_str |
1932 |
spelling |
Martinelli, Reinaldo PessôaPereira, Luiz JoséSilva, Oriana Maria Mattos eOkumura, Alice SetsukoRocha, Heonir de Jesus Pereira daMartinelli, Reinaldo PessôaPereira, Luiz JoséSilva, Oriana Maria Mattos eOkumura, Alice SetsukoRocha, Heonir de Jesus Pereira da2011-12-12T12:18:30Z2011-12-12T12:18:30Z20041678-4510http://www.repositorio.ufba.br/ri/handle/ri/480137(9)p.1365-1372Prednisone is the initial treatment of primary focal segmental glomerulosclerosis. However, when immunosuppressive agents in combination with steroids are used in the treatment of prednisone-dependent and prednisone-resistant patients the remission rate is variable. We report a long-term trial using cyclophosphamide (2.0 to 3.0 mg/kg body weight for 12 weeks) in combination with prednisone (1.0 to 2.0 mg/kg body weight), as compared with prednisone alone for the treatment of prednisone-resistant and frequently relapsing nephrotic syndrome and focal segmental glomerulosclerosis. Fifty-four patients (34 males and 20 females) with a diagnosis of idiopathic nephrotic syndrome and focal segmental glomerulosclerosis, followed-up for an average of 86.1 ± 82.4 months, were evaluated. Complete remission occurred in 20.4% and partial remission in 14.8% of the patients treated with steroids and in 26.7 and 20.0% of the patients treated with cyclophosphamide + prednisone, respectively. Of the 24 prednisoneresistant patients treated with steroids in combination with cyclophosphamide, 33.3% obtained a complete/partial response. At the time of final evaluation, 25% of the patients treated with prednisone and 10.0% of those treated with prednisone in combination with cyclophosphamide had reached end-stage renal disease. Persistent nephrotic syndrome and progressive renal insufficiency were more frequently observed among the patients treated with prednisone alone (50.0 vs 33.3% and 33.3 vs 16.7%, respectively). The treatments were well tolerated and no patient experienced adverse reactions requiring discontinuation of medications. Although open-label and non-randomized, the present trial showed that cyclophosphamide is a reasonable choice for the treatment of primary focal segmental glomerulosclerosis and prednisone-resistant nephrotic syndrome.Submitted by Ana Valéria de Jesus Moura (anavaleria_131@hotmail.com) on 2011-12-12T12:18:30Z No. of bitstreams: 1 4393.pdf: 516784 bytes, checksum: a882bf61fb5e7f2ec45963b67d858ae1 (MD5)Made available in DSpace on 2011-12-12T12:18:30Z (GMT). No. of bitstreams: 1 4393.pdf: 516784 bytes, checksum: a882bf61fb5e7f2ec45963b67d858ae1 (MD5) Previous issue date: 2004PrednisoneNephrotic syndromeCyclophosphamidePrimary glomerular diseaseFocal segmentalglomerulosclerosisCyclophosphamide in the treatment of focal segmental glomerulosclerosisBrazilian Journal of Medical and Biological Researchinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleengreponame:Repositório Institucional da UFBAinstname:Universidade Federal da Bahia (UFBA)instacron:UFBAinfo:eu-repo/semantics/openAccessLICENSElicense.txtlicense.txttext/plain1748https://repositorio.ufba.br/bitstream/ri/4801/2/license.txt8a4605be74aa9ea9d79846c1fba20a33MD52ORIGINAL4393.pdf4393.pdfapplication/pdf516784https://repositorio.ufba.br/bitstream/ri/4801/1/4393.pdfa882bf61fb5e7f2ec45963b67d858ae1MD51TEXT4393.pdf.txt4393.pdf.txtExtracted texttext/plain30397https://repositorio.ufba.br/bitstream/ri/4801/3/4393.pdf.txt4cf430cb8c16a2647f7696775e95b6cbMD53ri/48012022-07-05 14:03:16.885oai:repositorio.ufba.br:ri/4801Tk9URTogUExBQ0UgWU9VUiBPV04gTElDRU5TRSBIRVJFClRoaXMgc2FtcGxlIGxpY2Vuc2UgaXMgcHJvdmlkZWQgZm9yIGluZm9ybWF0aW9uYWwgcHVycG9zZXMgb25seS4KCk5PTi1FWENMVVNJVkUgRElTVFJJQlVUSU9OIExJQ0VOU0UKCkJ5IHNpZ25pbmcgYW5kIHN1Ym1pdHRpbmcgdGhpcyBsaWNlbnNlLCB5b3UgKHRoZSBhdXRob3Iocykgb3IgY29weXJpZ2h0Cm93bmVyKSBncmFudHMgdG8gRFNwYWNlIFVuaXZlcnNpdHkgKERTVSkgdGhlIG5vbi1leGNsdXNpdmUgcmlnaHQgdG8gcmVwcm9kdWNlLAp0cmFuc2xhdGUgKGFzIGRlZmluZWQgYmVsb3cpLCBhbmQvb3IgZGlzdHJpYnV0ZSB5b3VyIHN1Ym1pc3Npb24gKGluY2x1ZGluZwp0aGUgYWJzdHJhY3QpIHdvcmxkd2lkZSBpbiBwcmludCBhbmQgZWxlY3Ryb25pYyBmb3JtYXQgYW5kIGluIGFueSBtZWRpdW0sCmluY2x1ZGluZyBidXQgbm90IGxpbWl0ZWQgdG8gYXVkaW8gb3IgdmlkZW8uCgpZb3UgYWdyZWUgdGhhdCBEU1UgbWF5LCB3aXRob3V0IGNoYW5naW5nIHRoZSBjb250ZW50LCB0cmFuc2xhdGUgdGhlCnN1Ym1pc3Npb24gdG8gYW55IG1lZGl1bSBvciBmb3JtYXQgZm9yIHRoZSBwdXJwb3NlIG9mIHByZXNlcnZhdGlvbi4KCllvdSBhbHNvIGFncmVlIHRoYXQgRFNVIG1heSBrZWVwIG1vcmUgdGhhbiBvbmUgY29weSBvZiB0aGlzIHN1Ym1pc3Npb24gZm9yCnB1cnBvc2VzIG9mIHNlY3VyaXR5LCBiYWNrLXVwIGFuZCBwcmVzZXJ2YXRpb24uCgpZb3UgcmVwcmVzZW50IHRoYXQgdGhlIHN1Ym1pc3Npb24gaXMgeW91ciBvcmlnaW5hbCB3b3JrLCBhbmQgdGhhdCB5b3UgaGF2ZQp0aGUgcmlnaHQgdG8gZ3JhbnQgdGhlIHJpZ2h0cyBjb250YWluZWQgaW4gdGhpcyBsaWNlbnNlLiBZb3UgYWxzbyByZXByZXNlbnQKdGhhdCB5b3VyIHN1Ym1pc3Npb24gZG9lcyBub3QsIHRvIHRoZSBiZXN0IG9mIHlvdXIga25vd2xlZGdlLCBpbmZyaW5nZSB1cG9uCmFueW9uZSdzIGNvcHlyaWdodC4KCklmIHRoZSBzdWJtaXNzaW9uIGNvbnRhaW5zIG1hdGVyaWFsIGZvciB3aGljaCB5b3UgZG8gbm90IGhvbGQgY29weXJpZ2h0LAp5b3UgcmVwcmVzZW50IHRoYXQgeW91IGhhdmUgb2J0YWluZWQgdGhlIHVucmVzdHJpY3RlZCBwZXJtaXNzaW9uIG9mIHRoZQpjb3B5cmlnaHQgb3duZXIgdG8gZ3JhbnQgRFNVIHRoZSByaWdodHMgcmVxdWlyZWQgYnkgdGhpcyBsaWNlbnNlLCBhbmQgdGhhdApzdWNoIHRoaXJkLXBhcnR5IG93bmVkIG1hdGVyaWFsIGlzIGNsZWFybHkgaWRlbnRpZmllZCBhbmQgYWNrbm93bGVkZ2VkCndpdGhpbiB0aGUgdGV4dCBvciBjb250ZW50IG9mIHRoZSBzdWJtaXNzaW9uLgoKSUYgVEhFIFNVQk1JU1NJT04gSVMgQkFTRUQgVVBPTiBXT1JLIFRIQVQgSEFTIEJFRU4gU1BPTlNPUkVEIE9SIFNVUFBPUlRFRApCWSBBTiBBR0VOQ1kgT1IgT1JHQU5JWkFUSU9OIE9USEVSIFRIQU4gRFNVLCBZT1UgUkVQUkVTRU5UIFRIQVQgWU9VIEhBVkUKRlVMRklMTEVEIEFOWSBSSUdIVCBPRiBSRVZJRVcgT1IgT1RIRVIgT0JMSUdBVElPTlMgUkVRVUlSRUQgQlkgU1VDSApDT05UUkFDVCBPUiBBR1JFRU1FTlQuCgpEU1Ugd2lsbCBjbGVhcmx5IGlkZW50aWZ5IHlvdXIgbmFtZShzKSBhcyB0aGUgYXV0aG9yKHMpIG9yIG93bmVyKHMpIG9mIHRoZQpzdWJtaXNzaW9uLCBhbmQgd2lsbCBub3QgbWFrZSBhbnkgYWx0ZXJhdGlvbiwgb3RoZXIgdGhhbiBhcyBhbGxvd2VkIGJ5IHRoaXMKbGljZW5zZSwgdG8geW91ciBzdWJtaXNzaW9uLgo=Repositório InstitucionalPUBhttp://192.188.11.11:8080/oai/requestopendoar:19322022-07-05T17:03:16Repositório Institucional da UFBA - Universidade Federal da Bahia (UFBA)false |
dc.title.pt_BR.fl_str_mv |
Cyclophosphamide in the treatment of focal segmental glomerulosclerosis |
dc.title.alternative.pt_BR.fl_str_mv |
Brazilian Journal of Medical and Biological Research |
title |
Cyclophosphamide in the treatment of focal segmental glomerulosclerosis |
spellingShingle |
Cyclophosphamide in the treatment of focal segmental glomerulosclerosis Martinelli, Reinaldo Pessôa Prednisone Nephrotic syndrome Cyclophosphamide Primary glomerular disease Focal segmental glomerulosclerosis |
title_short |
Cyclophosphamide in the treatment of focal segmental glomerulosclerosis |
title_full |
Cyclophosphamide in the treatment of focal segmental glomerulosclerosis |
title_fullStr |
Cyclophosphamide in the treatment of focal segmental glomerulosclerosis |
title_full_unstemmed |
Cyclophosphamide in the treatment of focal segmental glomerulosclerosis |
title_sort |
Cyclophosphamide in the treatment of focal segmental glomerulosclerosis |
author |
Martinelli, Reinaldo Pessôa |
author_facet |
Martinelli, Reinaldo Pessôa Pereira, Luiz José Silva, Oriana Maria Mattos e Okumura, Alice Setsuko Rocha, Heonir de Jesus Pereira da |
author_role |
author |
author2 |
Pereira, Luiz José Silva, Oriana Maria Mattos e Okumura, Alice Setsuko Rocha, Heonir de Jesus Pereira da |
author2_role |
author author author author |
dc.contributor.author.fl_str_mv |
Martinelli, Reinaldo Pessôa Pereira, Luiz José Silva, Oriana Maria Mattos e Okumura, Alice Setsuko Rocha, Heonir de Jesus Pereira da Martinelli, Reinaldo Pessôa Pereira, Luiz José Silva, Oriana Maria Mattos e Okumura, Alice Setsuko Rocha, Heonir de Jesus Pereira da |
dc.subject.por.fl_str_mv |
Prednisone Nephrotic syndrome Cyclophosphamide Primary glomerular disease Focal segmental glomerulosclerosis |
topic |
Prednisone Nephrotic syndrome Cyclophosphamide Primary glomerular disease Focal segmental glomerulosclerosis |
description |
p.1365-1372 |
publishDate |
2004 |
dc.date.issued.fl_str_mv |
2004 |
dc.date.accessioned.fl_str_mv |
2011-12-12T12:18:30Z |
dc.date.available.fl_str_mv |
2011-12-12T12:18:30Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://www.repositorio.ufba.br/ri/handle/ri/4801 |
dc.identifier.issn.none.fl_str_mv |
1678-4510 |
dc.identifier.number.pt_BR.fl_str_mv |
37(9) |
identifier_str_mv |
1678-4510 37(9) |
url |
http://www.repositorio.ufba.br/ri/handle/ri/4801 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.source.none.fl_str_mv |
reponame:Repositório Institucional da UFBA instname:Universidade Federal da Bahia (UFBA) instacron:UFBA |
instname_str |
Universidade Federal da Bahia (UFBA) |
instacron_str |
UFBA |
institution |
UFBA |
reponame_str |
Repositório Institucional da UFBA |
collection |
Repositório Institucional da UFBA |
bitstream.url.fl_str_mv |
https://repositorio.ufba.br/bitstream/ri/4801/2/license.txt https://repositorio.ufba.br/bitstream/ri/4801/1/4393.pdf https://repositorio.ufba.br/bitstream/ri/4801/3/4393.pdf.txt |
bitstream.checksum.fl_str_mv |
8a4605be74aa9ea9d79846c1fba20a33 a882bf61fb5e7f2ec45963b67d858ae1 4cf430cb8c16a2647f7696775e95b6cb |
bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 MD5 |
repository.name.fl_str_mv |
Repositório Institucional da UFBA - Universidade Federal da Bahia (UFBA) |
repository.mail.fl_str_mv |
|
_version_ |
1808459389725573120 |